Clinical Trial
[The effects of somatostatin in acromegaly]
[Article in
French]
- PMID: 772591
Item in Clipboard
Clinical Trial
[The effects of somatostatin in acromegaly]
[Article in
French]
Nouv Presse Med.
.
Abstract
Somatostatine is the hypothalamic factor which inhibits the secretion of growth hormone. The administration of a synthetic form decreased growth hormone levels by 50 to 75% in 5 acromegalic patients. The action is rapid but the effect is not prolonged. Prolactin was reduced in only case with galactorrhea. Thyreostimulin, as well as gastrin, are unaffected. Plasma insulin levels, and to a lesser extent those of glucagon, are decreased by somatostatine which causes no variation in either cortisol or blood glucose. Somatostatine, by correcting the pathological secretion of hormone, opens the way to medical treatment of acromegaly.
Similar articles
-
Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.Acta Endocrinol Suppl (Copenh). 1987;286:9-18. Acta Endocrinol Suppl (Copenh). 1987. PMID: 2892339
-
Effect of somatostatin in patients with acromegaly: suppression of growth hormone, prolactin, insulin and glucose levels.N Engl J Med. 1974 Apr 25;290(17):935-8. doi: 10.1056/NEJM197404252901704. N Engl J Med. 1974. PMID: 4593614 No abstract available.
-
The somatostatin analogue SMS 201-995 in acromegaly: prolonged, preferential suppression of growth hormone but not pancreatic hormones.Clin Invest Med. 1987 Jul;10(4):309-15. Clin Invest Med. 1987. PMID: 2888554
-
Somatostatin: a review of its effects especially in human beings.Diabete Metab. 1976 Dec;2(4):203-18. Diabete Metab. 1976. PMID: 190058 Review.
-
[Somatostatin--a hypothalamic factor inhibiting the secretion of growth hormone].Pediatr Pol. 1977 Aug;52(8):919-23. Pediatr Pol. 1977. PMID: 333364 Review. Polish. No abstract available.